Document is current
Any future updates will be listed below
-
Authors
Bhatt, Surya P.
Freemantle, Nick
Soliman, Mena
Heble, Jigna
Cabon, Yann
Mayen Herrera, Ernesto
Yang, Joe
Xu, Yingxin
-
Funding
Funding for this research was provided by:
Regeneron Pharmaceuticals
Sanofi
- License Information
-
More Information
Article History
Received: 16 August 2025
Accepted: 16 September 2025
First Online: 26 September 2025
Declarations
:
: Surya P. Bhatt is supported by NIH grants R01HL151421 and UH3HL155806. The author serves on advisory boards and is a consultant for Apreo, AstraZeneca, Boehringer Ingelheim, Chiesi, Genentech, GSK, Merck, Polarean, Regeneron Pharmaceuticals Inc., Sanofi, and Verona Pharma; has received honoraria from Horizon CME, Integritas Communications, Illuminate Health, Integrity CE, and Medscape; and has received funds paid to their institute for research from COPD Foundation, Genentech, Nuvaira, and Sanofi. Nick Freemantle has received grants from Cure Parkinson’s Trust, European Union, Medical Research Council, and National Institute for Health and Care Research; consultancy fees from Abbott, Aimmune Therapeutics, ALK, AstraZeneca, Galderma, Gedeon Richter, Ipsen, Novo Nordisk, Sanofi, Théa Pharma, and Vertex Pharmaceuticals; and honorarium from Abbott Singapore. Mena Soliman, Joe Yang, and Yingxin Xu are employees and shareholders of Regeneron Pharmaceuticals Inc. Jigna Heble and Ernesto Mayen Herrera are employees of Sanofi and may hold stock and/or stock options in the company. Yann Cabon is an Aixial contractor for Sanofi and may hold stock and/or stock options in the company.
: This article is based on data from previously conducted trials and does not contain any new studies with human participants or animals performed by any of the authors. Please see the original publications for each trial for full details of ethical approvals.
